Analysis: Foreign Firms Hit With Majority Of FDA Quality-Linked Warning Letters Last Year
This article was originally published in The Silver Sheet
Executive Summary
Most of the 150 warning letters issued by FDA last year were sent to foreign manufacturers, a “Silver Sheet” analysis shows. That letters to overseas companies have outpaced those to domestic ones is a surprise given that the agency performs nearly four times as many inspections of U.S.-based facilities each year. But the foreign warning letter increase in 2013 might actually be a sign that FDA’s enhanced focus on overseas compliance in recent years has begun paying dividends. In related warning letter trends, CAPA has supplanted complaint handling as the No. 1 deficiency area cited in letters. Further, 56 close-out letters were sent to firms in 2013, down slightly from 2013.
You may also be interested in...
CDRH Compliance Office Looks Ahead To 2016
More emphasis on informal interactions with companies for minor concerns will be one hallmark of the FDA device center's Office of Compliance agenda for the coming year, according to Acting Director Sean Boyd, who provided an overview of the office's 2016 priorities.
FDA’s New Criminal Investigations Chief Wants Global Reach
Recently appointed Office of Criminal Investigations Director George Karavetsos talks about expanding the global presence of his office to protect product safety in the U.S. in an interview.
2014 Hot Spots: Top 4 Device Quality & Regulatory Topics
Big changes are afoot for inspections, and device stakeholders kept a sharp eye on those issues in 2014, according to readership data from "The Silver Sheet." From a CDRH/ORA plan to create a specialized unit of device-focused field investigators, to IMDRF's mostly untested internationally harmonized single-audit approach, readers (and podcast listeners) couldn't get enough news and tips about inspection activities. A recap of in-depth "Silver Sheet" coverage from the year, including updated expert commentary, follows.